natgillin/translations-raw huggingface dataset:
Patients with moderate or severe renal impairment require a dose interval adjustment of lamivudine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2). 
Bolesnicima s umjerenim ili teškim oštećenjem funkcije bubrega potrebna je prilagodba intervala doziranja lamivudina i tenofovirdizoproksila koja se ne može postići kombiniranom tabletom (vidjeti dijelove 4.4 i 5.2).
If you take more Delstrigo than you should Do not take more than the recommended dose. 
Nemojte uzeti više od preporučene doze.
In an in vivo mouse micronucleus assay, tenofovir disoproxil was negative when administered to male mice. 
U mišjem mikronukleusnom testu in vivo tenofovirdizoproksil je bio negativan kada je primijenjen mužjacima miševa.
Delstrigo should be discontinued if estimated CrCl declines below 50 mL per minute as dose interval adjustment required for lamivudine and tenofovir disoproxil cannot be achieved with the fixed dose combination tablet (see section 4.2). 
Primjenu lijeka Delstrigo treba prekinuti ako procijenjeni CrCl padne ispod 50 ml/min jer se potrebna prilagodba intervala doziranja lamivudina i tenofovirdizoproksila ne može postići tabletom s fiksnom kombinacijom doza (vidjeti dio 4.2).
Consistent results were seen for the comparison at Study Week 24 in each treatment group. 
Rezultati liječenja prikazani su u Tablici 5. Prilikom usporedbe u 24. tjednu ispitivanja, primijećeni su dosljedni rezultati u obje liječene skupine.
Lamivudine was not mutagenic in a microbial mutagenicity assay, in an in vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver. 
Lamivudin nije bio mutagen u testu mikrobne mutagenosti, testu stanične transformacije in vitro, mikronukleusnom testu na štakorima, citogenetskom testu na koštanoj srži štakora, kao ni u testu neplanirane sinteze DNK u jetri štakora.
No dose adjustment of doravirine/lamivudine/tenofovir disoproxil is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. 
Nije potrebno prilagođavati dozu doravirina/lamivudina/tenofovirdizoproksila u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre.
What Delstrigo looks like and contents of the pack Delstrigo is available as a yellow, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 776 on one side and plain on the other side. 
Delstrigo je žuta, ovalna filmom obložena tableta s utisnutim logotipom proizvođača i oznakom „776“ na jednoj strani i bez oznake na drugoj strani.
Lamivudine-resistant variants of HIV-1 have been selected in cell culture and in subjects treated with lamivudine. 
Varijante HIV-1 rezistentne na lamivudin izdvojene su u staničnoj kulturi i u ispitanika liječenih lamivudinom.
Lamivudine-resistant HIV-1 mutants were also cross resistant to didanosine (ddI). 
Mutirani oblici HIV-1 rezistentni na lamivudin također su pokazali križnu rezistenciju i na didanozin.
2031 BN Haarlem NETHERLANDS 
2031 BN Haarlem NIZOZEMSKA
HIV-1 isolates from patients (n = 20) whose HIV-1 expressed a mean of 3 zidovudine associated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir. 
Izolati HIV-1 u bolesnika (n=20) čiji HIV-1 eksprimira srednju vrijednost od 3 aminokiselinske supstitucije u reverznoj transkriptazi povezane s rezistencijom na zidovudin (M41L, D67N, K70R, L210W, T215Y/F ili K219Q/E/N) pokazali su 3,1 puta smanjenu osjetljivost na tenofovir.
A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established (see section 5.1). 
Nije utvrđena granična vrijednost za smanjenje osjetljivosti, uzrokovano različitim supstitucijama koje dovode do rezistencije na NNRTI-je, koje bi bilo povezano sa smanjenjem kliničke djelotvornosti (vidjeti dio 5.1).
The Phase 3 studies, DRIVE-FORWARD and DRIVE-AHEAD, included previously untreated patients (n = 747) where the following NNRTI substitutions were part of exclusion criteria: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V. 
U ispitivanjima faze 3 DRIVE-FORWARD i DRIVE-AHEAD sudjelovali su prethodno neliječeni bolesnici (n = 747), a sljedeće supstitucije povezane s rezistencijom na NNRTI-je bile su dio isključnih kriterija: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C,Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.
The DRIVE-SHIFT study included virologically suppressed patients (N=670) with no history of treatment failure (see section, Clinical experience). 
Odrasli ispitanici u kojih je postignuta virološka supresija Ispitivanje DRIVE-SHIFT uključilo je bolesnike u kojih je postignuta virološka supresija (N=670) i koji u anamnezi nemaju neuspješno liječenje (vidjeti dio Kliničko iskustvo).
The highest frequency category reported in the 3TC or TDF Summary of Product Characteristics is used. 
Navedena je najveća učestalost prijavljena u sažetku opisa svojstava lijeka za 3TC ili TDF.
Use with CYP3A inducers 
Primjena s induktorima CYP3A4
Keep the bottle tightly closed in order to protect from moisture. 
Bocu čuvati čvrsto zatvorenom radi zaštite od vlage.
Subjects were randomized to either switch to Delstrigo at baseline [N= 447, Immediate Switch Group (ISG)], or stay on their baseline regimen until Week 24, at which point they switched to Delstrigo [N= 223, Delayed Switch Group (DSG)]. 
Immediate Switch Group (ISG)] ili su ostali pri svom početnom režimu do 24. tjedna, nakon čega su prešli na Delstrigo [N=223, skupina s odgođenim prelaskom, engl.
Severe acute exacerbation of hepatitis B in patients co-infected with HIV-1 and HBV All patients with HIV-1 should be tested for the presence of hepatitis B virus (HBV) before initiating antiretroviral therapy. 
Sve bolesnike s HIV-1 infekcijom potrebno je testirati na prisutnost virusa hepatitisa B (HBV) prije uvođenja antiretrovirusne terapije.
Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with CrCl greater than 80 mL per minute of 243.5 ± 33.3 mL per minute (mean ± SD). 
Tenofovir se eliminira kombinacijom glomerularne filtracije i aktivne tubularne sekrecije, uz bubrežni klirens od 243,5 ± 33,3 ml/min (srednja vrijednost ± standardno odstupanje) u odraslih osoba kojima je CrCl veći od 80 ml/min.
The pharmacokinetics of tenofovir in non-haemodialysis adult subjects with CrCl < 10 mL/min and in subjects with end-stage renal disease managed by peritoneal or other forms of dialysis have not been studied. 
Farmakokinetika tenofovira nije se ispitivala u odraslih ispitanika kojima je CrCl < 10 ml/min i koji nisu na hemodijalizi niti u ispitanika u terminalnoj fazi bubrežne bolesti liječenih peritonejskom dijalizom ili nekom drugom vrstom dijalize.
• lesinurad (a medicine to treat gout) 
• lesinurad (lijek za liječenje gihta)
• increased levels of amylase 
• povišene vrijednosti amilaze
Doravirine/lamivudine/tenofovir disoproxil should not be co-administered with medicinal products that are strong CYP3A enzyme inducers as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of doravirine/lamivudine/tenofovir disoproxil (see sections 4.3 and 5.2). 
Doravirin/lamivudin/tenofovirdizoproksil ne smije se primjenjivati istodobno s lijekovima koji su snažni induktori enzima CYP3A jer se očekuju značajna sniženja koncentracija doravirina u plazmi, koja mogu smanjiti učinkovitost doravirina/lamivudina/tenofovirdizoproksila (vidjeti dijelove 4.3 i 5.2).
Clinical isolates containing the Y188L substitution or V106 substitutions in combination with A98G, H221Y, P225H, F227C or Y318F showed a greater than 100-fold reduced susceptibility to doravirine. 
Klinički izolati koji su sadržavali supstituciju Y188L ili supstitucije V106 u kombinaciji s mutacijama A98G, H221Y, P225H, F227C ili Y318F pokazali su više od sto puta smanjenu osjetljivost na doravirin.
The K70E substitution selected clinically by tenofovir disoproxil results in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir. 
Supstitucija K70E klinički izdvojena tenofovirdizoproksilom smanjuje osjetljivost na abakavir, didanozin, emtricitabin, lamivudin i tenofovir.
Hepatobiliary disorders Rare hepatic steatosis*, hepatitis* 
Poremećaji jetre i žuči rijetko steatoza jetre*, hepatitis*
None of the 24 subjects (11 in the immediate switch group, 13 in the delayed switch group) with baseline NNRTI mutations (RT K103N, G190A, or Y181C) experienced virologic failure through Week 48, or at time of discontinuation. 
Ni u jednog od 24 ispitanika (11 u skupini s prelaskom bez odgode, 13 u skupini s odgođenim prelaskom) s početnim mutacijama povezanima s rezistencijom na NNRTI-je (K103N, G190A ili Y181C u reverznoj transkriptazi) nije došlo do izostanka virološkog odgovora do 48. tjedna ili u trenutku prekida liječenja.
Mineralisation defects 
Poremećaji mineralizacije
Refill your prescription or talk to your doctor before your Delstrigo is all gone. 
Preuzmite novo pakiranje ili se obratite svom liječniku prije nego što potrošite sve tablete lijeka Delstrigo.
Tenofovir disoproxil is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. 
Tenofovirdizoproksil je aciklički nukleozidni fosfonatni diesterski analog adenozinfosfata.
• telotristat ethyl (a medicine to treat diarrhea in people with carcinoid syndrome) 
• etiltelotristat (lijek za liječenje proljeva u osoba s karcinoidnim sindromom)
For potential medicine product interactions with tenofovir disoproxil or lamivudine, (see sections 4.4 and 5.2). 
Za moguće interakcije tenofovirdizoproksila i lamivudina s drugim lijekovima (vidjeti dijelove 4.4 i 5.2).
HIV-1 isolates selected by tenofovir expressed a K65R substitution in HIV-1 RT and showed a 2-4 fold reduction in susceptibility to tenofovir. 
Izolati HIV-1 izdvojeni tenofovirom eksprimirali su supstituciju K65R u reverznoj transkriptazi HIV-1 te su pokazivali 2 - 4 puta smanjenu osjetljivost na tenofovir.
Delstrigo should be avoided with concurrent or recent use of nephrotoxic medicinal products (e.g., high-dose or multiple nonsteroidal anti-inflammatory medicinal products [NSAIDs]) (see section 4.5). 
Potrebno je izbjegavati primjenu lijeka Delstrigo istodobno ili neposredno nakon primjene nefrotoksičnih lijekova (npr. primjena visokih doza ili više različitih nesteroidnih protuupalnih lijekova [NSAIL] istovremeno) (vidjeti dio 4.5).
This is achieved by adding one 100 mg tablet of doravirine (as a single agent), to be taken approximately 12 hrs apart from the dose of Delstrigo (see section 4.5). 
To se postiže dodavanjem jedne tablete doravirina od 100 mg (kao monoterapije), približno 12 sati nakon doze lijeka Delstrigo (vidjeti dio 4.5).
Single-dose administration of one doravirine/lamivudine/tenofovir disoproxil tablet to healthy subjects (N = 24) under fasted conditions provided comparable exposures of doravirine, lamivudine, and tenofovir to administration of doravirine tablets (100 mg) plus lamivudine tablets (300 mg) plus tenofovir disoproxil tablets (245 mg). 
Jednokratna primjena jedne tablete doravirina/lamivudina/tenofovirdizoproksila zdravim ispitanicima (N=24) natašte dovela je do usporedivih razina izloženosti doravirinu, lamivudinu i tenofoviru kao i primjena zasebnih tableta doravirina (100 mg) plus lamivudina (300 mg) plus tenofovirdizoproksila (245 mg).
≥ 200 cells/mm 
≥ 200 stanica/mm
Expected:  norgestimate/ethinyl oestradiol 
Očekivano: ↔ norgestimat/etinilestradiol
Effects of doravirine, lamivudine, and tenofovir disoproxil on other medicinal products Doravirine 
Učinci doravirina, lamivudina i tenofovirdizoproksila na druge lijekove
Doravirine has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). 
Doravirin se nije ispitivao u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C).
Film-coating Carnauba wax (E903) Hypromellose (E464) Iron oxide yellow (E172) Lactose monohydrate Titanium dioxide (E171) Triacetin (E1518) 
Film ovojnica karnauba vosak (E903) hipromeloza (E464) željezov oksid, žuti (E172) laktoza hidrat titanijev dioksid (E171) triacetin (E1518)
Co-administration of doravirine with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. 
Istodobna primjena doravirina s drugim umjerenim induktorima CYP3A nije se ocjenjivala, ali očekuju se smanjene koncentracije doravirina.
Sedatives/Hypnotics midazolam (2 mg SD, doravirine 120 mg QD) 
Sedativi/hipnotici midazolam (2 mg SD, doravirin 120 mg QD)
A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established. 
Nije utvrđena granična vrijednost za smanjenje osjetljivosti, uzrokovano različitim supstitucijama koje dovode do rezistencije na NNRTI-je, koje bi bilo povezano sa smanjenjem kliničke djelotvornosti.
< 200 cells/mm 
< 200 stanica/mm
Doravirine has not been studied in patients with end-stage renal disease or in patients undergoing dialysis (see section 4.2). 
Doravirin se nije ispitivao u bolesnika u završnom stadiju bubrežne bolesti ni u bolesnika na dijalizi (vidjeti dio 4.2).
Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 12 times (mice) and 57 times (rats) the human exposures at the RHD. 
Dugoročna ispitivanja kancerogenosti lamivudina na miševima i štakorima nisu pokazala dokaze kancerogenog potencijala pri razinama izloženosti do 12 puta (miševi) odnosno 57 puta (štakori) većima od onih koje se postižu u ljudi kod primjene preporučene doze za ljude.
If the patient misses a dose of Delstrigo within 12 hours of the time it is usually taken, the patient should take Delstrigo as soon as possible and resume the normal dosing schedule. 
Ako je bolesnik propustio uzeti dozu lijeka Delstrigo, a od propuštene doze je prošlo manje od 12 sati, treba je uzeti što je prije moguće i zatim nastaviti s primjenom prema uobičajenom rasporedu.
• decreased levels phosphate 
• snižene razine fosfata
Doravirine does not inhibit the human cellular DNA polymerases α, ß, and mitochondrial DNA polymerase γ. 
Doravirin ne inhibira humane stanične DNK polimeraze α i ß ni mitohondrijsku DNK polimerazu γ.
Expected:  rosuvastatin  simvastatin 
Očekivano: ↔ rosuvastatin ↔ simvastatin
The pharmacokinetic properties of lamivudine have been determined in subjects with moderate to severe hepatic impairment. 
Farmakokinetičke značajke lamivudina određivale su se u ispitanika s umjerenim do teškim oštećenjem funkcije jetre.
• tacrolimus (a medicine used to control your body's immune response after a transplant) 
• takrolimus (lijek koji se koristi za kontroliranje odgovora imunološkog sustava nakon presađivanja)
Delstrigo 100 mg/300 mg/245 mg film-coated tablets. 
Delstrigo 100 mg/300 mg/245 mg filmom obložene tablete
The following de novo resistance was seen in the resistance analysis subset (subjects with HIV-1 RNA greater than 400 copies per mL at virologic failure or at early study discontinuation and having resistance data). 
U podskupini u kojoj je provedena analiza rezistencije (ispitanici kojima je razina HIV-1 RNK bila veća od 400 kopija/ml u trenutku izostanka virološkog odgovora ili prijevremenog povlačenja iz ispitivanja i za koje su postojali podaci o rezistenciji) opažena je sljedeća de novo rezistencija.
Successful genotype, n Genotypic resistance to DOR or control (DRV or EFV) 2 (DOR) 
DOR ili kontrola (DRV ili EFV)
Angiotensin Converting Enzyme Inhibitors lisinopril 
Inhibitori angiotenzin konvertirajućeg enzima lizinopril
Anticonvulsants carbamazepine oxcarbazepine phenobarbital phenytoin 
Antikonvulzivi karbamazepin okskarbazepin fenobarbital fenitoin
Blood and lymphatic systems disorders Uncommon neutropenia*, anaemia*, thrombocytopenia* 
Poremećaji krvi i limfnog sustava manje često neutropenija*, anemija*, trombocitopenija*
In DRIVE-AHEAD, 728 subjects were randomized and received at least 1 dose of either doravirine/lamivudine/tenofovir disoproxil 100/300/245 mg (DOR/3TC/TDF) or efavirenz/emtricitabine/tenofovir disoproxil (EFV/FTC/TDF) once daily. 
U ispitivanju DRIVE-AHEAD randomizirano je 728 ispitanika, koji su primili najmanje 1 dozu doravirina/lamivudina/tenofovirdizoproksila 100/300/245 mg (DOR/3TC/TDF) ili efavirenza/emtricitabina/tenofovirdizoproksila (EFV/FTC/TDF) jedanput na dan.
Because tenofovir is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion (see section 5.2), co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion via OAT1, OAT3 or MRP4 may increase serum concentrations of tenofovir. 
Budući da se tenofovir primarno eliminira putem bubrega kombinacijom glomerularne filtracije i aktivne tubularne sekrecije (vidjeti dio 5.2), istodobna primjena doravirina/lamivudina/tenofovirdizoproksila s lijekovima koji smanjuju funkciju bubrega ili se natječu za aktivnu tubularnu sekreciju putem prijenosnika OAT1, OAT3 ili MRP4 može povisiti koncentracije tenofovira u serumu.
Immunosuppressants tacrolimus sirolimus 
Imunosupresivi takrolimus sirolimus
Doravirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C) (see section 4.2). 
Doravirin se nije ispitivao u ispitanika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) (vidjeti dio 4.2).
Co-administration of doravirine/lamivudine/tenofovir disoproxil with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. 
Istodobna primjena doravirina/lamivudina/tenofovirdizoproksila s drugim umjerenim induktorima CYP3A nije se ocjenjivala, ali očekuju se smanjene koncentracije doravirina.
Expected:  doravirine ↑ tenofovir 
Očekivano: ↔ doravirin ↑ tenofovir
Biotransformation Based on in vitro data, doravirine is primarily metabolised by CYP3A. 
Prema podacima in vitro, doravirin se primarno metabolizira putem enzima CYP3A.
Effects of other medicinal products on doravirine, lamivudine, and tenofovir disoproxil Doravirine 
Učinci drugih lijekova na doravirin, lamivudin i tenofovirdizoproksil
Uncommon nightmare, depression 2, anxiety 3, irritability, confusional state, suicidal ideation 
• noćne more, depresija, tjeskoba, razdražljivost, smetenost, razmišljanje o samoubojstvu
Long-term oral carcinogenicity studies of doravirine in mice and rats showed no evidence of carcinogenic potential at estimated exposures up to 6 times (mice) and 7 times (rats) the human exposures at the RHD. 
Dugoročna ispitivanja kancerogenosti peroralno primijenjenog doravirina na miševima i štakorima nisu pokazala dokaze kancerogenog potencijala pri procijenjenim razinama izloženosti do 6 puta (miševi) i 7 puta (štakori) većima od onih koje se postižu u ljudi kod primjene preporučene doze za ljude.
Doravirine/lamivudine/tenofovir disoproxil must not be co-administered with other medicinal products containing lamivudine, or with medicinal products containing tenofovir disoproxil, or tenofovir alafenamide, or with adefovir dipivoxil (see section 4.5). 
Doravirin/lamivudin/tenofovirdizoproksil ne smije se primjenjivati istodobno s drugim lijekovima koji sadrže lamivudin, lijekovima koji sadrže tenofovirdizoproksil ili tenofoviralafenamid ni adefovirdipivoksilom (vidjeti dio 4.5).
• decreased levels of potassium in your blood 
• snižene razine kalija u krvi
Because lamivudine is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion (see section 5.2), co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of lamivudine. 
Budući da se lamivudin primarno eliminira putem bubrega kombinacijom glomerularne filtracije i aktivne tubularne sekrecije (vidjeti dio 5.2), istodobna primjena doravirina/lamivudina/tenofovirdizoproksila s lijekovima koji smanjuju funkciju bubrega ili se natječu za aktivnu tubularnu sekreciju može povisiti koncentracije lamivudina u serumu.
Table 5: Efficacy response (Snapshot approach) in the DRIVE-SHIFT study 
Snapshot approach) u ispitivanju DRIVE-SHIFT
Medicinal Product by Therapeutic Area 
Lijekovi po terapijskim područjima
The efficacy of switching from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors in combination with a ritonavir- or cobicistat-boosted PI, or cobicistat-boosted elvitegravir, or an NNRTI to Delstrigo was evaluated in a randomized, open-label trial (DRIVE-SHIFT), in virologically suppressed HIV-1 infected adults. 
Odrasli ispitanici u kojih je postignuta virološka supresija Djelotvornost prelaska na lijek Delstrigo s početnog režima koji se sastojao od dva nukleozidna inhibitora reverzne transkriptaze u kombinaciji s inhibitorom proteaze pojačanim ritonavirom ili kobicistatom ili elvitegravirom pojačanim kobicistatom, ili od NNRTI-ja, procijenjena je u randomiziranom ispitivanju otvorenog tipa (DRIVE-SHIFT) u odraslih ispitanika zaraženih HIV-om u kojih je postignuta virološka supresija.
The pharmacokinetics of doravirine were studied in healthy subjects and HIV-1-infected subjects. 
Farmakokinetika doravirina ispitivala se u zdravih ispitanika i ispitanika s HIV-1 infekcijom.
Delstrigo should be discontinued if estimated CrCl declines below 50 mL per minute (see section 4.4). 
Primjenu lijeka Delstrigo treba prekinuti ako procijenjeni CrCl padne ispod 50 ml/min (vidjeti dio 4.4).
Renal and urinary disorders Uncommon increased creatinine*, proximal renal tubulopathy (including Fanconi syndrome)* 
Poremećaji bubrega i mokraćnog sustava manje često povišene vrijednosti kreatinina*, proksimalna bubrežna tubulopatija (uključujući Fanconijev sindrom)*
Doravirine/lamivudine/tenofovir disoproxil should not be administered with doravirine unless needed for dose adjustment (e.g., with rifabutin) (see sections 4.2 and 4.5). 
Doravirin/lamivudin/tenofovirdizoproksil ne smije se primjenjivati u kombinaciji s doravirinom, osim u slučajevima kada je to potrebno zbog prilagodbe doze (npr. kod primjene istodobno s rifabutinom) (vidjeti dijelove 4.2 i 4.5).
Table 2: Tabulated summary of adverse reactions associated with doravirine/lamivudine/tenofovir disoproxil 
Tablica 2: Tablični prikaz nuspojava povezanih s primjenom doravirina/lamivudina/ tenofovirdizoproksila
If co-administration with other moderate CYP3A inducers (e.g., debrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, a 100 mg dose of doravirine should be administered daily, approximately 12 hours after the administration of doravirine/lamivudine/tenofovir disoproxil dose (see section 4.2). 
Ako se istodobna primjena s drugim umjerenim induktorima CYP3A (npr., dabrafenibom, lesinuradom, bosentanom, tioridazinom, nafcilinom, modafinilom, etiltelotristatom) ne može izbjeći, potrebno je primijeniti dozu doravirina od 100 mg na dan, približno 12 sati nakon doze doravirina/lamivudina/tenofovirdizoproksila (vidjeti dio 4.2).
Expected:  lisinopril 
Očekivano: ↔ lizinopril
• decreased levels of platelets in your blood (you may bleed more easily) 
• smanjen broj krvnih pločica u krvi (može povećati sklonost krvarenju)